CareDx (CDNA) CEO has 8,511 shares withheld for RSU tax obligations
CareDx, Inc.'s President and CEO, John Walter Hanna Jr., had 8,511 shares of common stock withheld by the company to cover tax obligations upon the vesting of restricted stock units. This transaction, valued at $29.25 per share, is a routine tax-withholding disposition and not an open-market sale. Following this action, Mr. Hanna Jr. directly holds 653,448 shares of CareDx common stock.
CareDx Leaders’ Audit Reforms Settlement Gets Court Approval
A US District Court judge has approved a settlement in which CareDx Inc. directors and executives agreed to implement audit reforms. This resolves a shareholder lawsuit alleging improper revenue-boosting schemes, including kickbacks and inaccurate marketing. The settlement also includes $594,000 in attorneys' fees and litigation expenses.
Enterprise value to EBITDA forward of CareDx, Inc. – NASDAQ:CDNA
This article provides financial context for CareDx, Inc. (NASDAQ: CDNA) focusing on its enterprise value to EBITDA forward metric. It appears to be a stub or data point from a financial platform, indicating the metric's value, change, and percentage change over a period. The content is primarily a data point embedded within a financial information service.
CDNA - Caredx Inc Short Interest
This article provides a detailed financial overview for Caredx Inc (CDNA), focusing on its short interest, key financial metrics, stock performance, and analyst recommendations. It highlights the company's market capitalization, income, sales, and various valuation ratios, alongside recent earnings data and insider/institutional ownership. The data presented covers share statistics, volatility, and performance across different timeframes, offering a comprehensive snapshot of CDNA's current market position.
CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology
CareDx, Inc. announced its acquisition of Naveris, adding its blood-based viral-mediated cancer detection product, NavDx, to CareDx's portfolio. NavDx, which includes Medicare coverage for HPV-driven head and neck and anal cancer surveillance, is expected to significantly contribute to CareDx's growth. This acquisition expands CareDx's leadership in precision diagnostic testing services in a market estimated to exceed $12 billion.
CareDx (CDNA) general counsel has 997 shares withheld for tax obligations
CareDx, Inc.'s Secretary and General Counsel, Jeffrey Adam Novack, had 997 shares of common stock withheld by the company to cover tax obligations related to the vesting of restricted stock units. This transaction, valued at $29.25 per share, is a routine administrative event and not an open-market sale. Following this withholding, Novack directly holds 111,635 shares of CareDx common stock.
CareDx (CDNA) CCO has shares withheld to cover taxes on RSU vesting
CareDx, Inc.'s Chief Commercial Officer, Jessica Meng, had 2,411 shares of common stock withheld by the company at $29.25 per share to cover tax obligations due to the vesting of restricted stock units. This transaction was a tax-related disposition, not an open-market sale. Following this, Meng directly owns 168,287 shares, which includes 1,306 shares acquired through the Employee Stock Purchase Plan.
CareDx (CDNA) CFO & COO reports RSU tax withholding, holds 219,924 shares
CareDx Inc.'s CFO and COO, Keith Kennedy, reported a routine tax-related share disposition. The company withheld 2,930 shares of common stock at $29.25 per share to cover tax obligations from the vesting of restricted stock units. Following this, Kennedy directly holds 219,924 CareDx shares, which includes 1,306 shares acquired through the Employee Stock Purchase Plan.
Eurobio Scientific Finalizes Acquisition of CareDx Lab Product Division
Eurobio Scientific has completed its acquisition of CareDx's lab products division, including subsidiaries in the U.S., Sweden, and Australia, for approximately €145 million ($170 million). This strategic move integrates GenDx’s next-generation sequencing assays with CareDx’s transplantation diagnostics, aiming to create a comprehensive portfolio for transplantation IVD workflow. The acquisition seeks to streamline laboratory operations, improve clinical outcomes, and strengthen GenDx’s market presence globally.
(CDNA) and the Role of Price-Sensitive Allocations
This article provides an AI-driven analysis of Caredx Inc. (NASDAQ: CDNA), highlighting strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It details three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. The quantitative research desk's analysis suggests an overweight bias for CDNA.
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
CareDx (Nasdaq: CDNA) has successfully completed its acquisition of Naveris, a company specializing in diagnostics for viral-mediated cancers. The acquisition expands CareDx's addressable market to over $12 billion across transplant, specialty oncology, and cell therapy, integrating Naveris's Medicare-covered NavDx test for HPV-positive head and neck and anal cancers. CareDx anticipates Naveris's approximately $35 million in 2025 revenue to be a significant contributor to its growth starting in the third quarter of 2026.
CareDx, Inc. completed the acquisition of Naveris, Inc. from B-Flexion Advisors (UK) LLP.
CareDx, Inc. has officially completed its acquisition of Naveris, Inc. from B-Flexion Advisors (UK) LLP. The deal, valued at an enterprise value of $160 million with potential for an additional $100 million based on revenue milestones, was initially agreed upon in April 2026. Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC acted as financial advisors for CareDx and Naveris respectively, with legal advice from Fenwick & West LLP and Skadden, Arps, Slate, Meagher & Flom LLP.
CareDx Closes Sale of Lab Products Business to Eurobio Scientific
CareDx has successfully completed the sale of its Lab Products business to Eurobio Scientific. This strategic move allows CareDx to focus on its core transplant testing services and comprehensive patient care, while Eurobio Scientific will integrate the acquired product portfolio to enhance its diagnostic offerings and market presence.
Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division
Eurobio Scientific has completed its acquisition of CareDx’s Lab Products division, integrating it with its GenDx affiliate. This strategic move aims to create a global leader in in-vitro molecular diagnostics for transplantation, enhancing capabilities in genomic typing and expanding product portfolios for HLA typing and transplant monitoring. The acquisition will bolster Eurobio Scientific's presence in key markets and accelerate innovation in transplantation diagnostics.
Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division
Eurobio Scientific has successfully acquired CareDx's Lab Products division, integrating its portfolio with Eurobio's affiliate GenDx. This acquisition is part of Eurobio's strategy to become a leader in in-vitro molecular diagnostics, creating a global provider of kits for genomic typing and transplantation diagnostics. The deal expands Eurobio Scientific's product offerings, enhances its global commercial scale, and fosters technological synergies in HLA typing and transplantation monitoring.
Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division
Eurobio Scientific has completed its acquisition of CareDx’s Lab Products division, including CareDx AB and its subsidiaries. This strategic move aims to accelerate Eurobio Scientific's goal of becoming a leader in in-vitro molecular diagnostics by integrating CareDx’s HLA typing kits with Eurobio's GenDx expertise, creating a comprehensive portfolio for transplantation diagnostics. The acquisition enhances their global market presence and technological capabilities, significantly expanding their offerings for transplantation IVD workflows.
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
CareDx, Inc. has completed the sale of its Lab Products business to Eurobio Scientific for $171.2 million in cash, following regulatory clearance. This divestiture allows CareDx to sharpen its focus on U.S. Precision Medicine Testing Services and Patient and Digital Solutions, particularly in high-growth areas like specialty oncology. The company expects to provide more financial details regarding the transaction during its second-quarter 2026 earnings call.
CareDx (CDNA) CEO exercises 70k options, sells 40k shares under 10b5-1 plan
CareDx (CDNA) President and CEO John Walter Hanna Jr. exercised employee stock options for 70,000 shares at $8.20 per share and subsequently sold 40,000 shares of common stock at a weighted average price of $29.244 per share. These sales, conducted on June 26 and June 29, 2026, were pre-arranged under a Rule 10b5-1 trading plan adopted on December 12, 2025. Following these transactions, Hanna directly owns 661,959 shares of CareDx common stock, indicating a routine liquidity event rather than a significant change in his stake.
Form 4 Caredx Inc For: 30 June By Investing.com
This article reports on a Form 4 filing for CareDx Inc. for June 30, as published by Investing.com. It indicates trading activity for the company (CDNA) with a slight stock performance decline. The main content also features various market data, including indices, commodities, and bonds, suggesting a broader financial context for the filing.
CareDx president and CEO John Hanna sells $1.17m stock By Investing.com
CareDx's President and CEO, John Hanna, sold 40,000 shares of the company's common stock for approximately $1.17 million between June 26 and June 29, 2026, under a Rule 10b5-1 trading plan. Concurrently, Hanna acquired 60,000 shares through employee stock options for $574,000. These transactions follow the company's strong Q1 financial results, including a 39% revenue increase, and strategic moves like selling its Lab Products business.
CareDx completes sale of lab products unit for $171.2M
CareDx (NASDAQ:CDNA) has completed the sale of its Lab Products business to Eurobio Scientific for $171.2 million in cash. This divestiture allows CareDx to focus on its U.S. precision medicine testing services and patient and digital solutions, aiming to simplify its operating model and support investments in high-growth areas like specialty oncology. The company's stock has seen positive market response, trading near its 52-week high and surging 55% year-to-date, though analysts suggest it may be overvalued at current levels.
Eurobio Scientific Société anonyme completed the acquisition of Caredx AB and Kitted Laboratory Products Business and Related Software of CareDx, Inc..
Eurobio Scientific Société anonyme has completed its acquisition of Caredx AB and the Kitted Laboratory Products Business and related software from CareDx, Inc. The acquisition involved a cash consideration of $170 million and was approved by the boards of both companies. This transaction integrates the acquired LabProducts division into GenDx's operations, aiming to ensure continuity for customers, partners, and employees.
CDNA: Insider Form 144 to sell 39,500 shares after option exercise (06/29/2026)
A Form 144 filing indicates a common stockholder of CareDx, Inc. (CDNA) intends to sell 39,500 shares of common stock on June 29, 2026, stemming from an exercise of stock options with cash proceeds. The filing also details several recent 10b5-1 sales by John Hanna, including transactions on June 11, June 15, and other dates, with specified share amounts and proceeds. This regulatory notice signals the planned transaction but does not confirm its completion.
Enterprise value to EBIT forward of CareDx, Inc. – NASDAQ:CDNA
The article focuses on the "Enterprise value to EBIT forward" metric for CareDx, Inc. (NASDAQ: CDNA). It appears to be a financial data page from TradingView, indicating that specific financial figures for this metric would be displayed, though the actual values are not present in this content snippet. The main purpose is to present this financial ratio for the company within the context of market data.
Caredx Inc stock hits 52-week high at $29.08 By Investing.com
CareDx Inc. (CDNA) stock reached a new 52-week high of $29.08, marking a 47.49% increase over the past year and a 53% year-to-date return. Despite this strong performance, InvestingPro analysis suggests the stock is currently overvalued. Recent company news includes a 39% revenue increase in Q1, the acquisition of Naveris for up to $260 million, and a raised price target from BTIG.
1K9 Forecast — Price Target — Prediction for 2027
This article provides a forecast for CareDx, Inc. (1K9) stock, including a consensus price target of 21.89 EUR from five analysts. It details the company's financial performance, such as recent earnings per share and revenue, and answers frequently asked questions about the stock's ticker, historical prices, and dividend policy. The report also lists the company's employee count and EBITDA figures.
Price to sales forward of CareDx, Inc. – BOATS:CDNA
This page displays the "Price to sales forward" metric for CareDx, Inc. (CDNA) on the Blue Ocean Alternative Trade System (BOATS). The specific financial data for this metric, including its value, change, and change percentage, is presented as "No trades" currently.
CareDx, Inc. Actuals & Estimates (NASDAQ:CDNA)
This article provides an in-depth overview of CareDx, Inc. (NASDAQ:CDNA) stock, including its current price, historical performance, analyst forecasts, and financial data. It details recent earnings, revenue, and market capitalization, offering insights into the company's financial health and future outlook. The article also addresses frequently asked questions about investing in CDNA stock.
1K9 Forecast — Price Target — Prediction for 2027
This article provides a forecast for CareDx, Inc. (1K9) stock, including analyst price targets and ratings. It details the company's financial performance, such as EPS and revenue for recent quarters, and lists key information like its earnings date, historical stock prices, and employee count. The article also clarifies that 1K9 does not pay dividends and offers guidance on how to buy its stocks.
CareDx Inc (CDNA) Institutional Confidence
CareDx Inc (CDNA) has an institutional shareholding score of 10.00, placing it first among 388 companies in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 101.54%, indicating a quarter-over-quarter decrease of 11.87%. Ron Baron is the largest institutional shareholder, holding 2.61 million shares, which represents 6.51% of shares outstanding.
Caredx Inc stock hits 52-week high at 26.7 USD
Caredx Inc (CDNA) stock reached a new 52-week high of $26.70, currently trading at $26.40, reflecting significant investor confidence and positive market sentiment. The company's market capitalization stands at $1.35 billion, with a 38.15% increase in stock value over the past year and a nearly 9% gain in the last week. Despite trading above its Fair Value according to InvestingPro analysis, recent positive news includes a 39% revenue increase in Q1, an acquisition deal for Naveris, and favorable analyst ratings.
CareDx (CDNA) Stock Could Be 1.5% Overvalued After AlloSure Study Buzz
CareDx (CDNA) is under scrutiny after new data from its AlloSure Registry and an 11.5% 1-day share price return. Analysts estimate the stock is 1.5% overvalued at $26.18 compared to a $25.80 fair value, with a consensus price target of $25.80 despite a broad range in individual analyst targets. However, the company's current P/S ratio of 3.3x is significantly below the industry average, suggesting potential for market revaluation if sentiment improves.
Responsive Playbooks and the CDNA Inflection
The article analyzes Caredx Inc. (NASDAQ: CDNA), indicating strong sentiment across all time horizons and predicting a breakout to higher levels due to an absence of resistance. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss parameters, supported by multi-timeframe signal analysis. The report highlights compelling upside potential for CDNA.
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?
CareDx (CDNA) shares recently rose 11.5% due to investor optimism following a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR) highlighting the utility of AlloSure Kidney. The company is expected to report a significant increase in quarterly earnings and revenues, with EPS projected to grow 120% year-over-year and revenues by 31.9%. Despite the positive outlook, the consensus EPS estimate has remained unchanged, and the stock currently holds a Zacks Rank #3 (Hold), prompting investors to monitor future earnings estimate revisions for sustained strength.
How New AlloSure Kidney Prognostic Evidence At CareDx (CDNA) Has Changed Its Investment Story
New evidence from the KOAR study and American Transplant Congress 2026 strengthens the clinical case for CareDx's AlloSure Kidney test, linking elevated levels to higher risks of allograft dysfunction and graft loss in kidney transplant recipients. While this clinical progress supports AlloSure's role as a prognostic tool, the investment narrative is still heavily influenced by potential reimbursement changes and pricing pressures. CareDx's long-term growth forecasts project significant revenue and earnings growth, yet analysts are divided on future revenue potential given evolving payer rules.
CareDx Inc (CDNA) Earnings Forecast: Future EPS & Revenue Growth Estimates
CareDx Inc (CDNA) currently has an earnings forecast score of 7.71 and ranks 274th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $24.50 for CDNA, with forecasts ranging from $14.00 to $28.00, and predominantly recommend a "Buy" for the stock. The company's expected revenue for the next quarter is $114.04 million, with an anticipated EPS of $0.23.
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
CareDx announced its significant participation at the 2026 American Transplant Congress, featuring over 30 abstracts and 9 oral presentations highlighting its precision medicine diagnostics. The data emphasizes AlloSure's evolving role, beyond surveillance, as a potential clinical endpoint for risk assessment, treatment response, and long-term graft outcomes across various organ transplants. Key studies presented findings in kidney, heart, and multi-organ transplantation, alongside advancements in next-generation biomarker discovery with HistoMap Kidney and ImmuneScape.
Insider Sell: CareDx Inc (CDNA) President and CEO Hanna John Wal
CareDx Inc.'s President and CEO, Hanna John Walter JR, sold 17,683 shares of the company on June 15, 2026, reducing his total holdings to 631,959 shares. Over the past year, the company has seen 15 insider sells and no insider buys. Based on a GF Value of $21.09, CareDx Inc. stock, trading at $24.03, is considered modestly overvalued.
CareDx Inc (CDNA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for CareDx Inc (CDNA), categorizing its revenue by business segment and by geographical region. The data, updated on April 6th, indicates that "Testing Service revenue" is the largest segment, and the United States accounts for the vast majority of its regional revenue. Financial figures are presented for various fiscal years and quarters up to FY2025.
CareDx Inc (CDNA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of CareDx Inc (CDNA) stock's dividend and stock split history. It states that CareDx Inc has distributed 0.00 USD in dividends over the past five years and reports no data for historical stock splits. The piece includes current stock price information and market capitalization for CDNA.
CareDx (CDNA) CEO sells 17,683 shares under 10b5-1 plan
John Walter Hanna Jr., President and CEO of CareDx (CDNA), sold 17,683 shares of common stock on June 15, 2026, at a weighted average price of $24.0274 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan established on December 13, 2024. Following the sale, Hanna Jr. continues to directly hold 631,959 shares of CareDx common stock.
CareDx Shareholders Back Directors, Auditor and Equity Plan
CareDx shareholders recently voted to elect five directors, ratify Deloitte & Touche LLP as the independent auditor, and approve an amendment to the 2024 Equity Incentive Plan to increase reserved shares. This move strengthens the company's governance and talent retention capabilities, with approximately 93% shareholder representation indicating strong support. An analyst rating for CDNA stock is currently Hold with a $21.91 price target, while TipRanks' AI Analyst Spark rates it as Outperform due to improving financials and price momentum.
CareDx (CDNA) director awarded 9,795 restricted stock units
CareDx, Inc. director Michael Goldberg was granted 9,795 restricted stock units (RSUs) as compensation, vesting 100% on the earlier of one year from the grant date or the day before the first Annual Meeting, contingent on his continuous service. This award, at no cash cost, increases his direct holdings to 195,737 shares of common stock.
CareDx (CDNA) director Fred E. Cohen receives 9,795-share RSU grant
CareDx (CDNA) director Fred E. Cohen was granted 9,795 restricted stock units (RSUs) as part of his equity compensation. These RSUs, which were awarded at no cash cost, will vest 100% on the earlier of one year from the grant date or the day before the first Annual Meeting after the grant, provided continuous service. Following this transaction, Cohen directly holds 165,060 shares of CareDx Common Stock.
CareDx (NASDAQ: CDNA) grants 9,795 RSUs to board member Riggsbee
CareDx, Inc. (NASDAQ: CDNA) director Richard Bryan Riggsbee has been granted 9,795 restricted stock units (RSUs) as equity compensation, not an open-market purchase. These RSUs vest 100% on the earlier of one year from the grant date or the day before the first Annual Meeting after the grant, subject to continuous service. Following this transaction, Riggsbee directly holds 39,312 shares of CareDx common stock.
Insider Sell: Hannah Valantine Sells 12,103 Shares of CareDx Inc (CDNA)
Hannah Valantine, a Director at CareDx Inc (CDNA), recently sold 12,103 shares of the company, bringing her total ownership to 36,686 shares. This transaction is part of a pattern of 15 insider sells and no buys over the past year for CareDx Inc. The stock is currently priced at $23.11, which suggests it is fairly valued according to GuruFocus's GF Value of $21.09.
CareDx Inc (CDNA) Shares Fall 3.4% -- GF Value Says Still Overva
CareDx Inc. (CDNA) shares dropped 3.4% to $23.22, significantly above its GF Value™ of $21.09, indicating it is overvalued. The company has an above-average GF Score™ of 77/100, driven by strong growth and financial strength, but a low profitability rank. Insider selling of $1.1 million over the past three months, with no buying, further suggests a cautious outlook on the stock.
CareDx (CDNA) director logs RSU grant and pre-planned share sale
CareDx, Inc. director Hannah Valantine reported receiving a grant of 9,795 restricted stock units on June 12, 2026, which vest based on service duration. Subsequently, on June 15, 2026, she sold 12,103 shares of Common Stock at a weighted average price of $23.1123 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Valantine directly holds 36,686 shares, indicating a routine compensation and liquidity event rather than a significant shift in her holdings.
CareDx study links kidney test elevations to graft loss risk By Investing.com
A study published in the Journal of the American Society of Nephrology, funded by CareDx Inc., revealed that elevated levels of donor-derived cell-free DNA (dd-cfDNA) measured by its AlloSure Kidney test are linked to a significantly higher risk of kidney allograft loss in transplant recipients. The analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR) found that patients with elevated AlloSure levels had a 3.7 to 6.4-fold increased adjusted hazard of graft loss, often detecting injury before a decline in kidney function was measurable. CareDx, a precision medicine company, is nearing its 52-week high, with strong Q1 2026 financial results, and is expanding through strategic acquisitions like Naveris.
CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
CareDx announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR) in the Journal of the American Society of Nephrology (JASN). The study found that elevations in AlloSure Kidney donor-derived cell-free DNA (dd-cfDNA) are associated with a significantly increased risk of graft dysfunction and loss in kidney transplant recipients, even when kidney function appears preserved. These findings support the use of AlloSure for longitudinal risk stratification and clinical decision-making to improve patient management.
